SERPINE1 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, SERPINE1 inhibitors (e.g., tiplaxtinin) combined with TKI exhibited stronger anti-leukemia effect than a single agent, while sparing normal stem/progenitor cells (Fig. 7), which supported that the combination treatment may benefit CML management.